Argenx Se (ARGX) Other Non-Current Liabilities (2016 - 2017)
Argenx Se's (ARGX) quarterly Other Non-Current Liabilities came in at $14.4 million in Q2 2017, up 9.14% on a QoQ basis from $13.2 million in Q4 2016.
Argenx Se (ARGX) Other Non-Current Liabilities (2016 - 2017) Analysis & Trends
Argenx Se (ARGX) has 2 years of Other Non-Current Liabilities data on file, last reported at $14.4 million in Q2 2017.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $14.4 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $14.4 million (changed N/A YoY) and the FY2016 annual result came in at $13.2 million, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $14.4 million in Q2 2017, from $13.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $14.4 million in Q2 2017 to a low of $13.2 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 14.37 Mn |
| Dec 31, 2016 | 13.16 Mn |